logo
Share SHARE
FONT-SIZE Plus   Neg

BMY, Pfizer Records Consistent Results In Sub-analysis Of Eliquis Vs. Warfarin

Bristol-Myers Squibb Co. (BMY) and Pfizer Inc. (PFE) said the Phase III Aristotle trial of Eliquis in comparison with warfarin for the the prevention of stroke or systemic embolism in nonvalvular atrial fibrillation were consistent with the overall results of the Aristotle trial. Further, the companies said the Eliquis compared with warfarin reduced stroke or systemic embolism, caused fewer major bleeding events, and reduced all-cause mortality in NVAF patients with or without valvular heart disease or VHD.

The Aristotle trial excluded patients with clinically significant mitral stenosis, or a mechanical prosthetic heart valve.

The results of the sub analysis were presented in an oral session today at the ESC Congress 2013 in Amsterdam, The Netherlands.

The subanalysis evaluated Eliquis compared to warfarin in patients with or without other types of VHD, who were eligible for enrollment in the Aristotle

trial, including mitral regurgitation, mitral stenosis, aortic regurgitation, aortic stenosis, tricuspid regurgitation, or valve surgery. 4,808 patients
participated in the sub analysis.

Eliquis is an oral inhibitor of blood clotting protein Factor Xa.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Everyone knows that the Federal Reserve will raise interest rates next Wednesday at the conclusion of its two-day policy meeting. After all, Fed speakers have been jawboning a rate hike over the past few weeks. With the markets reacting with eerie calm to Donald Trump's win, policy makers have no... GOP strategist Karl Rove has criticized U.S. President-elect Donald Trump's comments on aircraft maker Boeing Co.'s contract for a new Air Force One plane, saying they were inaccurate and de-stabled the stock of a major company. Air Force One is the official air plane for the U.S. President. Elon Musk's space transport company SpaceX has lost a satellite launch order from one of its customers due to the delay in its rocket launch schedule after one of its rockets exploded in September.
comments powered by Disqus
Follow RTT